325 related articles for article (PubMed ID: 14595509)
41. Seromucinous component in endometrioid endometrial carcinoma as a histological predictor of prognosis.
Miyamoto M; Takano M; Aoyama T; Soyama H; Yoshikawa T; Tsuda H; Furuya K
J Gynecol Oncol; 2018 Mar; 29(2):e20. PubMed ID: 29400013
[TBL] [Abstract][Full Text] [Related]
42. Molecular and cytokinetic pretreatment risk assessment in endometrial carcinoma.
Silverman MB; Roche PC; Kho RM; Keeney GL; Li H; Podratz KC
Gynecol Oncol; 2000 Apr; 77(1):1-7. PubMed ID: 10739683
[TBL] [Abstract][Full Text] [Related]
43. p53 aberrations in low grade endometrioid carcinoma of the endometrium with nodal metastases: possible insights on pathogenesis discerned from immunohistochemistry.
Fadare O; Parkash V
Diagn Pathol; 2017 Nov; 12(1):81. PubMed ID: 29137657
[TBL] [Abstract][Full Text] [Related]
44. Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer.
Lukes AS; Kohler MF; Pieper CF; Kerns BJ; Bentley R; Rodriguez GC; Soper JT; Clarke-Pearson DL; Bast RC; Berchuck A
Cancer; 1994 May; 73(9):2380-5. PubMed ID: 7909491
[TBL] [Abstract][Full Text] [Related]
45. Panel of Villin, Pro-Ex-C, Estrogen Receptor and Progesterone Receptor Expressions Could Help in Differentiation Between Endocervical and Endometrioid Adenocarcinoma.
Elfeky M; Harb O; Gertallah L
Turk Patoloji Derg; 2017; 1(1):29-40. PubMed ID: 28832070
[TBL] [Abstract][Full Text] [Related]
46. Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level.
Alkushi A; Lim P; Coldman A; Huntsman D; Miller D; Gilks CB
Int J Gynecol Pathol; 2004 Apr; 23(2):129-37. PubMed ID: 15084841
[TBL] [Abstract][Full Text] [Related]
47. Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases.
Darvishian F; Hummer AJ; Thaler HT; Bhargava R; Linkov I; Asher M; Soslow RA
Am J Surg Pathol; 2004 Dec; 28(12):1568-78. PubMed ID: 15577675
[TBL] [Abstract][Full Text] [Related]
48. Does high-grade endometrioid carcinoma (grade 3 FIGO) belong to type I or type II endometrial cancer? A clinical-pathological and immunohistochemical study.
Zannoni GF; Vellone VG; Arena V; Prisco MG; Scambia G; Carbone A; Gallo D
Virchows Arch; 2010 Jul; 457(1):27-34. PubMed ID: 20552366
[TBL] [Abstract][Full Text] [Related]
49. Immunohistochemical analysis of endometrial adenocarcinoma for bcl-2 and p53 in relation to expression of sex steroid receptor and proliferative activity.
Yamauchi N; Sakamoto A; Uozaki H; Iihara K; Machinami R
Int J Gynecol Pathol; 1996 Jul; 15(3):202-8. PubMed ID: 8811380
[TBL] [Abstract][Full Text] [Related]
50. Prognostic significance of overexpression of p53 in uterine endometrioid adenocarcinomas with an analysis of nuclear grade.
Urabe R; Hachisuga T; Kurita T; Kagami S; Kawagoe T; Matsuura Y; Shimajiri S
J Obstet Gynaecol Res; 2014 Mar; 40(3):812-9. PubMed ID: 24246002
[TBL] [Abstract][Full Text] [Related]
51. Supervised clustering of immunohistochemical markers to distinguish atypical endometrial hyperplasia from grade 1 endometrial cancer.
Laas E; Ballester M; Cortez A; Gonin J; Daraï E; Graesslin O
Gynecol Oncol; 2014 May; 133(2):205-10. PubMed ID: 24556060
[TBL] [Abstract][Full Text] [Related]
52. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?
Alvarez T; Miller E; Duska L; Oliva E
Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825
[TBL] [Abstract][Full Text] [Related]
53. Well differentiated endometrioid adenocarcinoma of the uterus: a cancer unit or centre case?
Montalto SA; Hakmi A; Moth P; Raju KS; Coutts M; Papadopoulos AJ; Devaja O
Eur J Gynaecol Oncol; 2009; 30(1):35-9. PubMed ID: 19317254
[TBL] [Abstract][Full Text] [Related]
54. Observations on tumor and metastatic suppressor gene status in endometrial carcinoma with particular emphasis on p53.
Ambros RA; Vigna PA; Figge J; Kallakury BV; Mastrangelo A; Eastman AY; Malfetano J; Figge HL; Ross JS
Cancer; 1994 Mar; 73(6):1686-92. PubMed ID: 8156496
[TBL] [Abstract][Full Text] [Related]
55. Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas.
Wu W; Slomovitz BM; Celestino J; Chung L; Thornton A; Lu KH
Cancer Res; 2003 Oct; 63(19):6195-9. PubMed ID: 14559803
[TBL] [Abstract][Full Text] [Related]
56. Endometrioid endometrial adenocarcinoma with psammoma bodies.
Parkash V; Carcangiu ML
Am J Surg Pathol; 1997 Apr; 21(4):399-406. PubMed ID: 9130986
[TBL] [Abstract][Full Text] [Related]
57. Effects of tamoxifen on steroid hormone receptors and hormone concentration and the results of DNA analysis by flow cytometry in endometrial carcinoma.
Nola M; Jukić S; Ilić-Forko J; Babić D; Uzarević B; Petrovecki M; Suchanek E; Skrablin S; Dotlić S; Marusić M
Gynecol Oncol; 1999 Mar; 72(3):331-6. PubMed ID: 10053103
[TBL] [Abstract][Full Text] [Related]
58. Clinical implications and prognostic value of single and combined biomarkers in endometrial carcinoma.
Li M; Zhao L; Shen D; Li X; Wang J; Wei L
Chin Med J (Engl); 2014; 127(8):1459-63. PubMed ID: 24762589
[TBL] [Abstract][Full Text] [Related]
59. Concurrent endometrial carcinoma in hysterectomy specimens in patients with histopathological diagnosis of endometrial hyperplasia in curettage specimens.
Dolanbay M; Kutuk MS; Uludag S; Bulut AN; Ozgun MT; Ozcelik B; Serin IS
Ginekol Pol; 2015 Oct; 86(10):753-8. PubMed ID: 26677585
[TBL] [Abstract][Full Text] [Related]
60. Impact of TP53 immunohistochemistry on the histological grading system for endometrial endometrioid carcinoma.
Yano M; Ito K; Yabuno A; Ogane N; Katoh T; Miyazawa M; Miyazawa M; Hasegawa K; Narahara H; Yasuda M
Mod Pathol; 2019 Jul; 32(7):1023-1031. PubMed ID: 30742011
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]